Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.36 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.34 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16384387 | 0.93 | TSHR (0.41) | USP2TSHRKMT2ACYP2C19CYP2D6 | |
| SCHEMBL12131751 | 0.89 | USP2 (0.55) | USP2TSHRKMT2ACYP2C19CYP2D6 | |
| SCHEMBL20346380 | 0.86 | KMT2A (0.50) | USP2TSHRKMT2ACYP2C19CYP2D6 | |
| SCHEMBL19961019 | 0.86 | KMT2A (0.50) | USP2TSHRKMT2ACYP2C19CYP2D6 | |
| SCHEMBL23567933 | 0.84 | ALDH1A1 (0.50) | KMT2ACYP2C19CYP2D6CYP2C9KISS1R | |
| SCHEMBL16384401 | 0.84 | ALDH1A1 (0.50) | KMT2ACYP2C19CYP2D6CYP2C9KISS1R | |
| SCHEMBL23696282 | 0.84 | ALDH1A1 (0.50) | KMT2ACYP2C19CYP2D6CYP2C9KISS1R | |
| SCHEMBL23696684 | 0.82 | CYP2D6 (0.40) | USP2TSHRKMT2ACYP2C19CYP2D6 | |
| SCHEMBL22525946 | 0.82 | ALDH1A2 (0.44) | KMT2ACYP2C19CYP2D6CYP2C9KISS1R | |
| SCHEMBL30393344 | 0.81 | USP2 (0.43) | USP2TSHRKMT2AKISS1RMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154303-A2 | DYNAMIC-COVALENT HYDROGELS WITH GLUCOSE-SPECIFIC AND GLUCOSE-RESPONSIVE DIBORONATE CROSSLINKING | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023057814-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| EP-4019518-A1 | TYK2 INHIBITORS AND USES THEREOF | Nimbus Lakshmi, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3432934-B1 | PRODRUGS OF CYTOTOXIC AGENTS WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma AG (DE) | 2022-02-23 | — | — | EP | disclosed |
| US-11208405-B2 | Pyrrole derivatives as PLK1 inhibitors | SENTINEL ONCOLOGY LIMITED (GB) | 2021-12-28 | — | — | US | disclosed |
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200247796-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-05-23 | — | — | US | disclosed |
| US-9931347-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (US) | 2018-04-03 | — | — | US | disclosed |
| WO-2017162663-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | WO | disclosed |
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-7807704-B2 | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 | CHEMOCENTRYX, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7671069-B2 | Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1323710-B1 | NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-7294457-B2 | Direct binding assay for identifying inhibitors of HCV polymerase | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2007-11-13 | — | — | US | disclosed |
| US-7282327-B2 | Nucleic acid labeling compounds | AFFYMETRIX, INC. (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | HNRNPH1, HNRNPH3, HNRNPUL2 | USP2 666/4885TSHR 3601/4885KMT2A 560/4885 |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | USP2 2473/4885TSHR 3165/4885KMT2A 3435/4885 |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | HNRNPH1, HNRNPH3, HNRNPUL2 | USP2 666/4885TSHR 3601/4885KMT2A 560/4885 |
| US-20200247796-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | PLK1, CDK1, AURKC | USP2 3796/4885TSHR 509/4885KMT2A 2079/4885 |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | MC2R, REN, CYP11B2 | USP2 4518/4885TSHR 1418/4885KMT2A 3551/4885 |
| US-11208405-B2 | Pyrrole derivatives as PLK1 inhibitors | PLK1, CDK1, AURKC | USP2 3796/4885TSHR 509/4885KMT2A 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.